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Branched-chain amino acid in chronic renal failure patients: Respira-
tory and sleep effects. Sleep disorders, including a high incidence of
sleep apnea, have been recognized as a significant problem in chronic
renal failure (CRF) patients. In a preliminary study, we examined CRF
patients on maintenance hemodialysis for three nights; one control
night, and thereafter randomized to infusion of saline (placebo) for one
night and 4% branch-chain amino acid (BCAA) solution for one night.
Polysomnographic and respiratory data [respiratory rate, oxygen satu-
ration and end-tidal CO2 (ETCO2)J was recorded continuously through-
out the nights and data from each hour compared with baseline (awake)
values. The patients studied were characterized by reduced sleep
quality and decreased amount of rapid eye movement (REM) sleep. The
BCAA infusion was associated with a return of REM sleep to normal
and a significant decrease in ETCO2 during both REM and non-REM
sleep (P < 0.05). Our findings demonstrate respiratory stimulation
during sleep with infusion of BCAA; this stimulatory effect on respira-
tion (in contrast to many respiratory stimulants) is associated with an
increased amount of REM sleep.
Sleep disorders have become a topic of increasing clinical
interest in chronic renal failure (CRF) patients on hemodialysis
(HD) [1—3]. The sleep disorder may take the form of an
abnormal pattern of sleep and increased requirements for
medication as well as an overt sleep apnea. Both obstructive
apnea (no airflow but respiratory effort) and central apnea (no
airflow and no respiratory effort) occur in CRF patients [2, 41.
The detrimental clinical effects of sleep apnea include arterial
oxygen desaturation, cardiac arrhythmias, and pulmonary and
systemic hypertension [5]. Although the effects of an abnormal
pattern of sleep are less clinically severe, nonetheless these
patients frequently report daytime drowsiness and fatigue
which limit functional capacity. Mood and personality disorders
as well as impaired intellectual functioning may also be ob-
served [6, 7]. Conventional hemodialysis has not been found to
modulate the severity of sleep apnea [3]. Significant improve-
ments in both physiology and symptomatology have been
reported with different pharmacological agents such as theo-
phyllamin, acetazolamid, and protrityfine [6—10]. However,
potential side effects (peripheral neuropathy, paresthesia, aci-
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dosis, impotence, and dry mouth) and changes in sleep quality
have limited the use of these agents [6, 9, 10].
Takala et al [lii demonstrated that infusion of branch-chain
amino acid (BCAA) enriched solutions magnify the increase in
ventilatory chemosensitivity to CO2 observed with regular
amino acid solutions [12, 131. As a consequence, the minute
ventilation increased significantly, and a significantly decreased
arterial PaCO2 was observed as well. In a previous study [14] of
normal subjects we found that nocturnally infused BCAA was
associated with no changes in sleep quality but with a signifi-
cantly decreased end-tidal CO2 (ETCO2). This observation was
probably due to improved alveolar gas exchange [11]. Intrave-
nous BCAA administration is considered to be without toxic
side effects, and BCAA may therefore be an useful alternative
as respiratory stimulant in treatment of sleep apnea.
With this background, we found it of interest to study the
effects of nocturnally infused BCAA on respiratory patterns
and sleep in a group of CRF patients undergoing maintenance
hemodialysis (HD). This study could then act as a basis for
further investigations of the role of intradialytic BCAA admin-
istration in CRF patients with sleep disorders.
Methods
Patienis
Patients were selected from the Baumritter Kidney Center's
in-center hemodialysis population. A standard questionnaire
was administered to all patients. Those patients who reported
remarkable sleep disturbances (several awakenings during the
night, difficulties in falling asleep, daily drowsiness, etc.) were
considered for the study. Written informed consent was ob-
tained from all subjects, and the study was approved by the
Institutional Review Board of The Albert Einstein College of
Medicine at Montefiore Medical Center.
Seven CRF patients (3 female and 4 male) treated with HD
three times a week agreed to undergo nocturnal polysomnogra-
phy and were studied on three nights prior to HD on the
following day. None of the patients had concomitant liver, heart
or lung diseases. Patients were dialyzed according the kinetic
modeling principles developed by Gotch and Sargent [15], and
achieved kinetic modeling parameters (KT/V) of 1.0 or greater,
which is accepted as an indicator of adequate dialysis. Patients
treated with sedatives or antihistamines had to discontinue
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PCO2 mm Hg 40.4 3.0
P02 mm Hg 93.4 4.5
Base excess mmol/liter 3.1 5.7
Sleep pattern
Stages land2% 66±12 63±9
Stages3and4% 19±9 12±6
REMsleep% 14±8 23±4
Sleep efficiency % 70 12 97 2
Sleep latency mm 21 15 6 4
Data are presented as mean SD. Normal values are based on
international standards applied by sleep laboratories, matched with age
and sex. Definitions are: sleep efficiency = total sleep time divided with
total recording time; sleep latency = the interval between lights out and
sleep onset.
them during the study period. Six of the patients were on
antihypertensive medications, including beta blockers. The
polysomnographic investigation revealed that only one patient
had severe sleep apnea. This patient was very different from the
rest both with respect to sleep and respiratory pattern, and he is
therefore presented separately. The mean age of the six patients
without apnea was 43 years (range 36 to 48 years). Their mean
dry weight given as the percent of ideal body weight (The
Revised Metropolitan Ideal Body Weight Tables, 1985) was
91% (range 76 to 110%). Table 1 shows patient characteristics of
the six non-apneic patients.
Procedure
No food intake was allowed after 5 p.m. on any of the three
study nights. On infusion nights, a peripheral line (22G) was
inserted in the arm contralateral to the arterio-venous dialysis
access. The patients did not receive any infusion the first night
(control). They were subsequently randomized, in double-
blind, cross over fashion, to receive either BCAA (60 mg/kg/hr
= 1.4 mI/kg/hr. corresponding to 100 ml/hr in a 70kg person) or
saline, intravenously, for seven hours on the two study nights.
The infusions were started one hour before habitual bedtime.
The BCAA solution (4% Branchamin-Baxter) contained 1.38 g
of isoleucine and leucine each per 100 ml, and 1.24 g of valine
per 100 ml.
Surface electrodes and a 12 channel Grass P78 polysomno-
graph (PSG) were employed for continuous recording of the
electroencephalogram, submental electromyelogram, electro-
oculogram, and electrocardiogram [4, 161. Respiratory move-
ments were monitored with pneumograph bellows around the
chest and abdomen and recorded on the PSG [4]. The pneumo-
graph bellows were used in a semiquantitative fashion to allow
differentiation of obstructive and central apneas and hypo-
pneas.
A finger oximeter (Ohmeda Biox 3700, Ohmeda, Lousville,
Colorado, USA) with an accuracy of 1.5% and a capnograph
(Normocap, Datex, Helsinki, Finland) with an accuracy of
were used to record oxyhemoglobin saturation (Sa02) and
ETCO2 [4, 171. To measure ETCO2 a length of thin tubing was
inserted about 1 cm into the nostril and the other end connected
to the sample port of a capnograph [4, 181. The capnograph was
calibrated prior to each night's study. Both the oximeter and
capnograph were connected to the PSG for continuous record-
ing. The presence of airflow was inferred by the ETCO2 and by
thermocouples at the nose and mouth.
Data analysis
The polysomnograms were scored for sleep stages and inci-
dence, length and severity of apneas/hypopneas by a registered
polysomnographic technologist unfamiliar with the premises of
the study. Following the traditional staging and scoring defini-
tions introduced originally by Rechtshaffen and Kales [191,
sleep was divided into REM (rapid eye movement) sleep and
non-REM sleep (Stages Ito IV) [4, 161. Stages I and II comprise
light sleep, whereas stages III and IV constitute slow or delta
wave sleep. Sleep progresses through these stages to REM
sleep. In this paper, sleep stages and REM sleep are expressed
as percentages of total sleep time.
Obstructive apnea was defined as the absence of airflow in
the presence of rib cage and abdominal excursions for a period
of at least 10 seconds, while non-obstructive (central) apnea
was defined as the absence of both airflow and respiratory
movement for at least 10 seconds [2, 4, 6]. Apneas with both
obstructive and central characteristics ("mixed") were classi-
fied together with the obstructive apneas [4]. Hypopnea was
defined as an episode of at least 10 seconds in which the
amplitude of the sum of ventilatory movement of rib cage and
abdomen was less than 50% of the mean amplitude of the
previous breaths. Five or more apneas per hour of sleep was
considered abnormal and apnea associated with more than 5%
desaturation was considered severe.
Analysis of ETCO,, Sa02, and respiratory and heart rate was
carried out during blocks of three to five minutes of stable
breathing (no apneas) in every sleep stage that was recorded
during each hour of the sleep study. Only CO2 polygraph
waveforms consisting of a sharp upstroke and downstroke with
a relatively flat plateau which had a slightly ascending slope
were considered valid for analysis of ETCO, [4, 18, 20]. During
each hour, the block selected for analysis was as close as
possible to the middle of the hour. Thus, the measurements of
breaths during each hour of sleep avoided potential bias asso-
ciated with selecting breaths from only one point in time during
the night of polysomnography [211. The baseline consisted of a
five minute block of stable breathing after the patient retired
and before onset of sleep. Mean values were obtained by
averaging all measurements over the three to five minute
periods. Data from baseline were compared to hourly measure-
ments from midnight to 5 a.m. This particular period was
chosen since some patients did not fall asleep until midnight and
many of them had to get up at 5 a.m. for early dialysis. The data
from non-REM periods analyzed were for stages 1 and 2
because adequate data for stages 3 and 4 were missing in many
patients. The patients had infrequent periods of REM sleep,
which usually occurred at the end of the study period. There-
fore, data from the last recorded REM period was used for
comparison with baseline and non-REM values.
Statistical analysis was performed using SYSTAT software
(Evanston, Illinois, USA). A repeated measures model was
used (MANOVA) to control for possible individual differences
and to compare the three measurement periods. Post-hoc
comparisons were made by the Tukey test. When applicable,
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Table 2. Polysomnographic and respiratory data (N 6)
P
Saline BCAA value
Stagel% 9±3 6±3 NS
Stage 2 % 56 19 53 10 NS
Stages 3 and 4 % 21 14 20 II NS
REM sleep % 12 10 19 8 <0.05
Sleep efficiency % 66 16 74 13 NS
Sleep latency mm 39 35 12 10 = 0.11
Arousals total 30 12 35 14 NS
Arousals >5 mm 5 3 5 2 NS
Apnea index number/hr of sleep 2 2 2 3 NS
Apnea-hypopnea index 3 4 4 5 NS
number/hr of sleep
Baseline Sa02 % 97 2 96 I NS
Lowest Sa02 % 90 3 88±5 NS
Data are presented as means 5D.
for paired data the Student's I-test was performed, A P value
less than 0.05 was considered statistically different.
Results
Seven patients completed the three night study. Compared to
values for their age-matched normal subjects (based on the
international standards applied by sleep laboratories) the six
patients without sleep apnea were characterized by both less
REM sleep and reduced sleep quality, as evidenced by prolon-
gation in time to fall asleep and reduced time spent in sleep
during the night as compared with normal reference values
(Table 1). When sleep and respiratory data from the night of
BCAA and saline infusion was compared, a significant increase
in REM sleep (P < 0.05) was found with BCAA (Table 2). A
reduction in time to fall asleep with BCAA was observed, but
the difference did not reach statistical significance.
Baseline ETCO2 for each night was compared with values for
each hour throughout the night. On the placebo (saline) night no
changes in ETCO2 could be measured. With BCAA, however,
there was a significant decrease (11%) in mean ETCO2 during
the seven hours of infusion both for non-REM (P < 0.05) and
REM sleep (P < 0.05; Fig. 1). Respiratory rate (ranging in
means between 16 to 19 breaths/mm) and Sa02 (in mean range
of 94.5% to 96%) did not change significantly from baseline
throughout the study nights, nor were there any significant
changes in heart rate.
Patient #7 (Table 3) had severe sleep apnea and also differed
from the other patients in that he was overweight (150% of ideal
body weight). The patient had markedly reduced sleep effi-
ciency on both nights (Table 3). Due to continuous arousals in
connection with the apneas his sleep was scored as transitional
sleep, type non-REM and REM [4, 19]. There was no significant
increase in the ratio of REM to non-REM sleep when compar-
ing the night of saline and BCAA (Table 3). However, the
BCAA night in this patient was associated with a large decrease
in the total number of obstructive apneas, corresponding to a
fall in the apnea index from 85 to 31. Furthermore, no central
apneas occurred that night, and the mean duration of both
obstructive apneas and hypopneas was lowered with BCAA (30
vs. 26 sec, and 30 vs. 20 see, respectively). These changes were
also associated with improvements in oxygen saturation. While
the apneas on the saline night were associated with regular
desaturations from a baseline of 95% decreasing to about 40%,
the hypopneas and majority of the apneas seen on the BCAA
night only caused desaturation down to around 70%. On both
nights the apnea induced desaturation was worse during REM
sleep. Despite improvements with BCAA, the severity of his
sleep apnea made this patient a candidate for trial of nocturnal
Continuous Positive Airway Pressure (CPAP) mask [4, 6], and
he was referred for this.
Discussioti
Abnormalities of sleep pattern with reduced sleep quality are
common in CRF patients on HD. However, few studies have
been undertaken to look at pathogenesis and treatment of sleep
disturbances in these patients [221. When compared to age-
matched values for normal range, our patients showed poorer
sleep quality (less time spent in sleep, increased time to fall
asleep and less REM sleep). Further, the larger standard
deviations of sleep parameters compared to the values for
normal subjects indicated markedly larger interindividual vari-
ations. Although this study was designed to observe potential
changes in ventilation, the unexpected finding of an improve-
ment in REM sleep was observed. The infusion of BCAA
significantly increased the percentage of REM sleep in our
patients. It also tended to reduce the time before falling asleep
(sleep latency) but did not improve actual time spent in sleep
(sleep efficiency). No changes in the non-REM sleep stages
were found.
In our study the infusion of BCAA appeared to stimulate
respiration. The decrease in ETCO2 found with BCAA in our
study is in agreement with previous studies of both awake and
asleep normal subjects [11, 14]. The use of ETCO2 to monitor
ventilation during sleep studies is well established [4, 18]. GOthe
et al [18] showed that in normal subjects sleep was associated
with decreased ventilation and a rise in ETCO2. Kirvelä et al
[14] also interpreted the decrease in ETCO2 with BCAA as a
sign of improved ventilation during sleep. Takala et al [11],
however, measured changes in PaCO2 and ventilatory response
to CO2 inhalation during BCAA infusion and correlated this to
minute ventilation, tidal volumes and metabolic rate. We mea-
sured ETCO2 and assumed that in these fasting and resting
subjects the only change in CO2 production would be due to
BCAA infusion. Therefore, the changes in ETCO2 would cor-
respond to changes in respiratory drive to a similar degree as in
the study of Takala et al [11]. In patients without pathological
dead-space ventilation, ETCO2 corresponds well with alveolar
CO2. and hence PaCO2, as long as only normal capnographic
waveforms are analyzed [4, 20]. None of our patients had
symptomatic lung disease. We therefore believe the decrease in
ETCO2 during BCAA infusion in our patients can be taken as a
sign of increased respiratory drive and improved alveolar
ventilation [11, 18]. The infusion rate of BCAA in the present
study was the same as in the study of awake normals [11], but
we used 100% instead of 85% BCAA solution. Unlike the study
in awake normals [11], we did not observe any significant
increase in respiratory rate with BCAA.
Kimmel, Miller and Mendelsohn [2] found that the incidence
of sleep apnea in CRF patients was close to 10%. They further
showed that in approximately half of the patients, sleep apneas
were primarily of the obstructive type. In the rest, more than
half of the apneas and hypopneas were of central origin. In the
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Table 3. Sleep and respiratory data for Patient #7 (m







Sleep efficiency % 55% 47%
Total number apnea 323 94
Obstructive 319 94
Central 4 0
Apnea index 85 31
Total number hypopneas 190 395




one patient with severe obstructive sleep apnea in our study
group, BCAA reduced both the total number of apneas and the
severity of oxygen desaturation in the remaining apneas and
hypopneas. The oximeter used in our study has previously been
tested for accuracy down to oxygen saturation levels of 40%
and found reliable within 2 to 3% [17]. Therefore, we believe
that observed differences in oxygen saturation are authentic and
not due to technical errors. Although the beneficial response
seen in this patient is only preliminary and may have been
influenced by other factors, such as physiological night-to-night
variability in the severity of sleep apnea, this case report may
still be of importance in that it indicates the necessity for further
studies about the usefulness of BCAA in the treatment of sleep
apnea in CRF patients.
At present, the use of respiratory stimulants in sleep apnea is
controversial [5, 6, 10]. Besides the high incidence of toxic
side-effects, the main critique of pharmacological interventions
in sleep apnea has been concurrent worsening of sleep quality
[6, 9, 23]. In CRF patients the majority of sleep apneas occur in
non-REM sleep stages I and II [2]. Previously, the use of
respiratory stimulants has been associated with increased
amounts of such light and unsteady non-REM sleep, thereby
counteracting the other positive effects on sleep apnea [6, 23].
Importantly, this was not the case with BCAA. Since REM
sleep is generally associated with worsening of sleep apnea [4],
the increased amount of REM sleep in our patients is an aspect
that needs further consideration.
The mechanism of the augmented respiratory effects and
changes in sleep pattern seen with BCAA infusion is unknown.
Alteration in plasma amino acids with elevated levels of BCAA
competing for transportation across the blood-brain barrier with
amino acids, which act as precursors for neurotransmitters, has
been proposed as a mechanism [ii, 14]. In CRF patients this
hypothesis may be of particular relevance, since both serum
BCAA depletion and specific changes in cerebral uptake of
amino acids have been associated with CRF [24—26].
In conclusion, BCAA was found to significantly improve
ventilation during sleep, reflected by a decrease in ETCO2. This
was achieved with an increased percentage of REM sleep and
thus with a improvement of the disturbed sleep pattern ob-
served in these patients. Taken as preliminary evidence, in the
one patient with severe obstructive sleep apnea, the total
number of apneas and the severity of desaturation in the
remaining apneas and hypopneas were reduced during BCAA
infusion. We think these results necessitate further investiga-
tions demonstrating whether BCAA is useful in the treatment of
sleep apnea in CRF patients, and perhaps in ameliorating the
sleep disorders which often accompany CRF. This improve-
ment in sleep quality may reduce hypersomnolence and cogni-
tive dysfunctioning during daytime, with a reduced requirement
for sedative hypnotic medication, and thus enhance the pa-
tients' rehabilitation and quality of life.
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Fig. 1. End-tidal CO2 during nocturnal infusion of
— — — saline (El) and of4% BCAA () solution (mean
Mid-infusion End-infusion SE). There was significant decrease in mean ETCO2
(non-REM (non-REM (REM sleep) during the BCAA infusion both for non-REM and
sleep) sleep) REM sleep (P 0.05).
Baseline
(awake)
Transitional sleep a Sleep continuously interrupted by arousals [4]
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